{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:05:03Z","timestamp":1784178303828,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>OBI-3424 is an investigational small-molecule prodrug. In a dose-escalation trial, the OBI-3424 recommended phase 2 dose (RP2D) was 12\u2009mg\/m2 administered every 21\u2009days. In this phase 2 dose-expansion trial, we evaluated the safety and efficacy of OBI-3424 in pancreatic adenocarcinoma and other solid tumor types (\u201cbasket\u201d cohort).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with advanced solid tumors and an AKR1C3 IHC H-score of \u2265 100 were treated at the RP2D of OBI-3424. Tumor response, progression-free survival (PFS), overall survival (OS), and treatment-emergent adverse events (TEAEs) were assessed (www.clinicaltrials.gov NCT03592264).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 29 patients treated, 26 were evaluable for response (pancreatic adenocarcinoma, n\u2009=\u200910; basket cohort, n\u2009=\u200916). In the pancreatic adenocarcinoma cohort, stable disease (SD) was observed in 40.0% of patients, and the median PFS and OS durations were 1.35\u2009months and 3.8\u2009months, respectively. In the basket cohort, the objective response rate was 6.3% (1 of 16 patients had a partial response), 50% of patients had SD, and the median PFS and OS durations were 2.53\u2009months and 5.32\u2009months, respectively. The most common TEAEs in both cohorts were anemia, fatigue, and thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While OBI-3424 demonstrated a favorable safety profile, limited efficacy led to early trial termination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag254","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:46:20Z","timestamp":1782920780000},"source":"Crossref","is-referenced-by-count":0,"title":["Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-233X","authenticated-orcid":false,"given":"Apostolia Maria","family":"Tsimberidou","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Verschraegen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center , Columbus, OH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Sigal","sequence":"additional","affiliation":[{"name":"Scripps Clinic and Scripps Cancer Center , La Jolla, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-9568","authenticated-orcid":false,"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-1529","authenticated-orcid":false,"given":"Howard","family":"Hochster","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute , New Brunswick, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet A","family":"Baysal","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8623-8311","authenticated-orcid":false,"given":"Ingly","family":"Lee","sequence":"additional","affiliation":[{"name":"OBI Pharma USA, Inc. , San Diego, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koenuel","family":"Ristoski","sequence":"additional","affiliation":[{"name":"OBI Pharma USA, Inc. , San Diego, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[{"name":"OBI Pharma USA, Inc. , San Diego, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026071600262030500_oyag254-B1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.abb.2007.04.024","article-title":"Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms","volume":"464","author":"Penning","year":"2007","journal-title":"Arch Biochem Biophys"},{"key":"2026071600262030500_oyag254-B2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cbi.2014.09.024","article-title":"The aldo-keto reductases (AKRs): overview","volume":"234","author":"Penning","year":"2015","journal-title":"Chem Biol Interact"},{"key":"2026071600262030500_oyag254-B3","first-page":"2419","article-title":"Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung","volume":"6","author":"Chang","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"2026071600262030500_oyag254-B4","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","article-title":"The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3","volume":"70","author":"Guise","year":"2010","journal-title":"Cancer Res"},{"key":"2026071600262030500_oyag254-B5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/erc.1.01048","article-title":"Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase\/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma","volume":"13","author":"Fung","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"2026071600262030500_oyag254-B6","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"key":"2026071600262030500_oyag254-B7","first-page":"278","article-title":"Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma","volume":"5","author":"Miller","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"key":"2026071600262030500_oyag254-B8","first-page":"505","article-title":"The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs","volume":"63","author":"Desmond","year":"2003","journal-title":"Cancer Res"},{"key":"2026071600262030500_oyag254-B9","doi-asserted-by":"crossref","first-page":"102027","DOI":"10.1016\/j.tranon.2024.102027","article-title":"AKR1C3 promotes progression and mediates therapeutic resistance by inducing epithelial-mesenchymal transition and angiogenesis in small cell lung cancer","volume":"47","author":"Liu","year":"2024","journal-title":"Transl Oncol"},{"key":"2026071600262030500_oyag254-B10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2119\/molmed.2012.00296","article-title":"Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer","volume":"18","author":"Hamid","year":"2013","journal-title":"Mol Med"},{"key":"2026071600262030500_oyag254-B11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mce.2008.04.004","article-title":"AKR1C2 and AKR1C3 mediated prostaglandin d2 metabolism augments the PI3K\/Akt proliferative signaling pathway in human prostate cancer cells","volume":"289","author":"Wang","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"2026071600262030500_oyag254-B12","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.18632\/aging.202380","article-title":"Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"2026071600262030500_oyag254-B13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1535-7163.MCT-16-0186","article-title":"Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2026071600262030500_oyag254-B14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/1471-2407-12-381","article-title":"Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization","volume":"12","author":"Heibein","year":"2012","journal-title":"BMC Cancer"},{"key":"2026071600262030500_oyag254-B15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-14-3080","article-title":"Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"2026071600262030500_oyag254-B16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.7150\/ijms.9239","article-title":"AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells","volume":"11","author":"Zhao","year":"2014","journal-title":"Int J Med Sci"},{"key":"2026071600262030500_oyag254-B17","doi-asserted-by":"crossref","first-page":"e111911","DOI":"10.1371\/journal.pone.0111911","article-title":"Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress","volume":"9","author":"Xiong","year":"2014","journal-title":"PLoS One"},{"key":"2026071600262030500_oyag254-B18","doi-asserted-by":"crossref","first-page":"48050","DOI":"10.18632\/oncotarget.10347","article-title":"Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"2026071600262030500_oyag254-B19","first-page":"3645","article-title":"A novel selective AKR1C3-activated prodrug AST-3424\/OBI-3424 exhibits broad anti-tumor activity","volume":"11","author":"Meng","year":"2021","journal-title":"Am J Cancer Res"},{"key":"2026071600262030500_oyag254-B20","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-19-0551","article-title":"OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of t-all","volume":"25","author":"Evans","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026071600262030500_oyag254-B21","author":"OBI","year":"2018"},{"key":"2026071600262030500_oyag254-B22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41416-023-02280-4","article-title":"Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors","volume":"129","author":"Tsimberidou","year":"2023","journal-title":"Br J Cancer"},{"key":"2026071600262030500_oyag254-B23","doi-asserted-by":"crossref","first-page":"635808","DOI":"10.3389\/fgene.2021.635808","article-title":"Human alkbh6 is required for maintenance of genomic stability and promoting cell survival during exposure of alkylating agents in pancreatic cancer","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Genet"},{"key":"2026071600262030500_oyag254-B24","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"2026071600262030500_oyag254-B25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2014.12.018","article-title":"Improving drug delivery to solid tumors: Priming the tumor microenvironment","volume":"201","author":"Khawar","year":"2015","journal-title":"J Control Release"},{"key":"2026071600262030500_oyag254-B26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","article-title":"Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends Cancer"},{"key":"2026071600262030500_oyag254-B27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"2026071600262030500_oyag254-B28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","article-title":"Precision nanomedicine: Navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery","volume":"24","author":"Sabit","year":"2025","journal-title":"Mol Cancer"},{"key":"2026071600262030500_oyag254-B29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13046-019-1153-8","article-title":"Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment","volume":"38","author":"Looi","year":"2019","journal-title":"J Exp Clin Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag254\/68681986\/oyag254.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag254\/68681986\/oyag254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag254\/68681986\/oyag254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:26:34Z","timestamp":1784175994000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag254\/8723503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag254","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"oyag254"}}